Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: A retrospective analysis

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 4, 2004, Pages 1148-1156

  Kouloulias, Vassilios E ^a   Kouvaris, John R ^a   Kokakis, John D ^a   Kostakopoulos, Athanasios ^b   Mallas, Elias ^a   Metafa, Anna ^a   Vlahos, Lambros J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alopecia; Amifostine; Dermatitis; Interval; Mucositis; Radiotherapy; Retrospective analysis

Indexed keywords

BIOLOGICAL ORGANS; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; TUMORS;

CYTOPROTECTIVE IMPACT; SARCOMAS;

ONCOLOGY;

AMIFOSTINE; ANTIHISTAMINIC AGENT; HYDROCORTISONE SODIUM SUCCINATE;

ALLERGIC REACTION; ASTHENIA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROTECTION; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; FLUID THERAPY; GYNECOLOGIC CANCER; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOTENSION; INFORMATION RETRIEVAL; KIDNEY CANCER; LUNG CANCER; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NASOPHARYNX CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; REVIEW; SCORING SYSTEM; SOFT TISSUE CANCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TASTE DISORDER; TUMOR LOCALIZATION; VOMITING; XEROSTOMIA;

EID: 3042651070     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.12.013     Document Type: Article

References (40)

1. Davidson D.E., Grenan M.M., Sweeney T.R. Biological characteristics of some improved radioprotectors. Brady L. Radiation sensitizers. 1980;209-214 Masson Press, New York
2. Schuchter L.M., Glick J. The current status of WR-2721 (amifostine) A chemotherapy and radiation therapy protector. Biologic Ther Cancer. 3:1993;1-10
3. Coleman N., Bump E., Kramer R. Chemical modifiers of cancer treatment. J Clin Oncol. 6:1988;709-733
4. Calabro-Jones P., Aguilera J., Ward J., et al. Uptake of amifostine derivatives by cells in culture Identification of the transported form of the drug. Cancer Res. 48:1988;3634-3640
5. Lindegaard J.C., Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol. 57:2000;113-118
6. Yuhas J.M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)- ethylphosphorothioic acid. Cancer Res. 40:1980;1519-1524
7. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer. 32A:(Suppl. 4):1996;S5-S16
8. Capizzi R.L. Amifostine The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 23:(Suppl. 8):1996;2-17
9. McCauley D.L. Amifostine A novel cytoprotective agent. Cancer Pract. 5:1997;189-191
10. Blumberg A.L., Nelson D.F., Gramkowski M., et al. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys. 8:1982;561-563
11. Kouvaris J., Kouloulias V., Malas E., et al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol. 179:2003;167-174
12. Kouvaris J., Kouloulias V., Kokakis J., et al. The cytoprotective effect of amifostine in acute radiation dermatitis A retrospective analysis. Eur J Dermatol. 12:2002;458-462
13. Kouvaris J., Kouloulias V., Kokakis J., et al. Cytoprotective effect of amifostine in radiation-induced acute mucositis retrospective analysis. Onkologie. 25:2002;364-369
14. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 17:1999;3333-3355
15. Shaw L.M., Turrisi A.T.I., Glover D.J., et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 12:1986;1501-1504
16. van der Vijgk W.J.F., Korst A.E.C. Amifostine (Ethyol) Pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer. 32A:(Suppl. 4):1996;S26-S30
17. World Health Organization. Handbook for reporting results of cancer treatment. 1979;World Health Organization, Geneva, Switzerland
18. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria, version 2.0 An improved reference for grading the acute effects of cancer treatment - Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:2000;13-47
19. Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria, Appendix B. http://www.rtog.org/members/toxicity/main.html
20. Leavens M.E., McCutcheon I.F., Samaan N.A. Management of pituitary adenomas. Oncology (Huntngtn). 66:1992;69-79
21. Bukowski R.M. Amifostine (Ethyol) Dosing, administration and patient management guidelines. Eur J Cancer. 32A:(Suppl. 4):1996;S46-S49
22. Siegel S., Castellan J.N. Jr. Nonparametric statistics for the behavioral sciences. 2nd ed:1988;McGraw Hill, New York
23. Hosmer D.W., Lemeshow S. Applied logistic regression. 1989;John Wiley & Sons, New York
24. Shaw L.M., Turrisi A.T., Glover D.J., et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 12:1986;1501-1504
25. Shaw L.W., Glover D.J., Turrisi A., et al. Pharmacokinetics of WR-2721. Pharmacol Ther. 39:1988;195-201
26. Shaw L.M., Bonner H.S., Brown D.Q. Metabolic pathway of WR-2721 (Ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos. 22:1994;895-902
27. Shaw L.M., Glover D., Turrisi A., et al. Pharmacokinetics of WR2721. Pharmacol Ther. 39:1998;195-201
28. Utley J.F., Seaver N., Newton G.L., et al. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys. 10:1984;1525-1528
29. Withers H.R., Taylor J.M.G., Maciejewski B. The hazards of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146
30. Rasey J.S., Grunbaum Z., Krohn K.A., et al. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913). Radiat Res. 102:1985;130-137
31. 2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Biol. 61:1992;533-537
32. Wasserman H.T. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol. 21:(Suppl. 11):1994;21-25
33. Archambeau J.O., Pezner R., Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys. 31:1995;1171-1185
34. McChesney S.L., Gillette E.L., Dewhirst M.W., et al. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 12:1986;1957-1963
35. Treskes M., Nijtmans L., Fichtinger-Schepman A.M., et al. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts. Anticancer Res. 12:1992;2261-2265
36. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 14:1996;2101-2112
37. Kligerman M.M., Liu T., Liu Y., et al. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. Int J Radiat Oncol Biol Phys. 22:1992;799-802
38. Liu T., Liu Y., Zhang Z., et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer. 69:1992;2820-2825
39. Milas L.D., Murray A.W., Brock W.A., et al. Radioprotectors in tumor radiotherapy Factors and settings determining therapeutic ratio. Pharmacol Ther. 39:1988;179-187
40. Schuchter L.M. Guidelines for the administration of amifostine. Semin Oncol. 23:(Suppl. 8):1996;40-43